ÁøÇ༺ µÎ°æºÎ¾Ï¿¡ ´ëÇÑ FCL(5-FU, Carboplatin, Leucovorin) º¹ÇÕÈÇпä¹ý
Effect of FCL(5-FU, carboplatin, Leucovorin) Chemotherapy in Advanced Head and Neck Cancer
¼Ò¼Ó »ó¼¼Á¤º¸
±è»ï¿ë
ÃÖÁö¿µ/±èöÈñ/¹è±¤ºÀ/±èÇö¼ö/±èÁ¾¼÷/¹Ú»óÁØ/À±È¯Áß/±èº´±¹
KMID : 0360319970290010038
Abstract
°á·Ð
ÁøÇàµÈ µÎ°æºÎ¾Ï¿¡¼ cisplatinÀ» Æ÷ÇÔÇÑ º¹ÇÕÈÇпä¹ýÀº ºñ±³Àû ³ôÀº ¹ÝÀÀÀ²À» º¸ÀÌÁö¸¸
cisplatin¿¡ ÀÇÇÑ ¿©·¯ ºÎÀÛ¿ëÀº ȯÀÚÀÇ »îÀÇ ÁúÀ» ÀúÇϽÃų ¼ö ÀÖ´Ù. ¹Ý¸é °°Àº platinum°è
ÀÎ carboplatinÀº ÈξÀ ºÎÀÛ¿ëÀº ÀûÀ¸¸é¼ ºñ½ÁÇÑ Ç×¾Ï È¿°ú¸¦ Áö´Ñ °ÍÀ¸·Î º¸°íµÇ°í ÀÖ´Ù
1993³â 3¿ùºÎÅÍ 1996³â 4¿ø±îÁö Ãæ³²´ëÇб³º´¿ø¿¡ ³»¿øÇÏ¿© µÎ°æºÎ¾ÏÀ¸·Î Áø´Ü ¹ÞÀº 22¸íÀÇ
ȯÀÚ¸¦ ´ë»óÀ¸·Î 5-FU´Â 500mg/m2, carboplatinÀº 400 mg/m2
·Î Åõ¿©ÇÏ¿´°í leucovorinÀº 20mg/m2ÀÇ ¿ë·®À¸·Î ÇÑ FCL(5-FIT,
carboplatin, leucovorin) º¹ÇÕÈÇпä¹ýÀº ¸Å 3¡4ÁÖ¸¶´Ù ½ÃÇàÇÏ¿´À¸¸ç ´ÙÀ½°ú °°Àº °á°ú¸¦
¾ò¾ú´Ù.
1) ÆÇÁ¤ °¡´ÉÇÑ 20¿¹ Áß ¿ÏÀü¹ÝÀÀ 1¿¹(5%), ºÎºÐ ¹ÝÀÀ 8¿¹(40%)·Î Àüü ¹ÝÀÀÀ²Àº 45%¿´´Ù.
2) Æò±Õ 35°³¿ù ÃßÀû°üÂû ÇÑ °á°ú ¹ÝÀÀÀ¯Áö±â°£ÀÇ Áß¾ÓÄ¡´Â 24ÁÖ(4-¡70+)¿´´Ù.
3)Æò±Õ 35°³¿ù ÃßÀû°á°ú »ýÁ¸±â°£Àº 3-¡21+¿´À¸¸ç »ýÁ¸±â°£ÀÇ Áß¾ÓÄ¡´Â 12°³¿ùÀ̾ú´Ù.
4) FCL º¹ÇÕÈÇпä¹ý Áß ³ªÅ¸³ Ç÷¾×ÇÐÀû ºÎÀÛ¿ëÀº ¹éÇ÷±¸°¨¼Ò(WHO G¡Ã2) 9.1%, Ç÷¼ÒÆÇ
°¨¼Ò (WHO G¡Ã2) 1.3%·Î °æ¹ÌÇÏ¿´´Ù. ºñÇ÷¾×ÇÐÀûµ¶¼ºÀº ¿À½É, ±¸Åä(WHO G¡Ã2)°¡ 15.6%,
±¸³»¿° (WHO G¡Ã2) 7.8%·Î ³ªÅ¸³µ´Ù. ±× ÀÌ¿Ü¿¡ ½Åµ¶¼ºÀ̳ª ½Å°æµ¶¼ºÀÇ ºÎÀÛ¿ëÀº ³ªÅ¸³ª
Áö ¾Ê¾Ò´Ù.
ÀÌ»óÀÇ °á°ú´Â FCL º¹ÇÕÈÇпä¹ýÀÌ cisplatinÀÇ º¹ÇÕÈÇпä¹ýº¸´Ù ÈξÀ ºÎÀÛ¿ëÀÌ ´úÇϸç
±¹¼Ò ÁøÇàµÇ¾ú°Å³ª ÀüÀÌ°¡ µ¿¹ÝµÈ µÎ°æºÎ¾Ï¿¡¼ È¿°úÀûÀ̶ó°í »ç·áµÈ´Ù.
#ÃÊ·Ï#
Purpose : The purpose of this study was to evaluate the efficacy and the toxicities of
recently developed second generation platinum, carboplatin in combination with
5-fluorouracil and leucovorin in head and neck cancer patients.
Patients and Methods : Between March 1993 and Aprils 1996, 22 patients with locally
advanced/metastatic head and neck cancer were treated with FCL combination
chemotherapy Of these 20 patients were evaluable.
Results : Median age was 58 years. The number of patients with stage ¥² and ¥³
patients was 4 and 18 respectively. Among the 20 evaluable patients, 1(7.2%) achieved a
complete response and 8(40%) achieved partial responses. The median duration of the
response was 24 weeks and the median survival duration was 12 months. Out of 77
chemotherapy cycles, 1 patient(1.3%) had anemia of WHO grade 2, 7 patients (9.1%)
experienced leukopenia(WHO grade ¡Ã2) and 7(9.1%) experienced thrombocytopenia
(WHO grade ¡Ã2). Non-hematologic toxicities were mild; nausea and voming of WHO
grade ¡Ã 2 was 12(15.6%), stomatitis(WHO grade ¡Ã 2) was 6(7.8%).
Conclusion : FCL chemotherapy was effective in locally advanced head and neck
cancer. Toxocities were minimal compared to cisplatin based combination chemotherapy.
Further studies on increased dose of FCL chemotherapy in head and neck cancer
patients is warranted.
Å°¿öµå
Head and neck cancer; Carboplatin; FCL chemotherapy;
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸